| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/30-1/150 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | P2Y14; BPR105; GPR105 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human P2RY14 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是生成的示例参考文献(内容为虚构，仅作演示)：
---
1. **"P2RY14 Antibody Development for Targeting Glioma Microenvironment"**
*Author: Li et al. (2022)*
**摘要**: 研究开发了高特异性P2RY14抗体，验证其在胶质瘤微环境中通过抑制P2RY14介导的炎症信号通路减少肿瘤生长的效果。
2. **"Role of P2RY14 in Diabetic Nephropathy and Antibody-Based Therapeutic Strategies"**
*Author: Smith & Kumar (2021)*
**摘要**: 利用P2RY14抗体阻断肾脏细胞中受体的过度激活，证实其可减缓糖尿病肾病模型中的纤维化进程。
3. **"P2RY14-Specific Antibodies Modulate Immune Cell Migration in Chronic Inflammation"**
*Author: Garcia et al. (2020)*
**摘要**: 通过单克隆抗体靶向P2RY14.揭示了该受体在巨噬细胞趋化中的作用，为治疗慢性炎症疾病提供新思路。
4. **"Commercial P2RY14 Antibodies: Validation and Applications in Flow Cytometry"**
*Author: Chen et al. (2019)*
**摘要**: 系统评估了市售P2RY14抗体的特异性及在流式细胞术中的应用，优化了免疫细胞亚群的检测方案。
---
注：以上文献为模拟内容，实际引用需检索PubMed/Google Scholar等数据库获取真实文献。
The P2RY14 antibody is a research tool designed to target the P2Y14 receptor, a G protein-coupled receptor (GPCR) belonging to the purinergic receptor family. P2Y14 (P2RY14) is activated by extracellular uridine diphosphate glucose (UDP-glucose) and related sugar-nucleotides, coupling primarily to Gi/o proteins to modulate intracellular signaling pathways such as cAMP inhibition and calcium mobilization. It is expressed in immune cells (e.g., dendritic cells, neutrophils), epithelial tissues, and the central nervous system, where it plays roles in inflammation, immune responses, and metabolic regulation. Dysregulation of P2Y14 has been implicated in diseases like asthma, diabetes, and cancer, making it a potential therapeutic target.
P2RY14 antibodies are typically monoclonal or polyclonal and are utilized in techniques like Western blotting, immunohistochemistry (IHC), and flow cytometry to study receptor localization, expression levels, and function in physiological or pathological contexts. Their development faces challenges due to the structural complexity of GPCRs and low endogenous receptor expression in certain tissues. Recent advancements in antibody engineering have improved specificity, enabling better characterization of P2Y14's role in UDP-glucose-mediated signaling and its crosstalk with other receptors. These antibodies also aid in validating P2Y14 as a biomarker or testing pharmacological inhibitors in preclinical models, bridging basic research and therapeutic exploration.
×
